All In MedTech

Device Trial Radar · NCT03600168

Post-Market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Liver Surgery

A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of Purastat Absorbable Haemostatic Material for the Management of Bleeding After Open Liver Resection

Last checked: Nov 20, 2026Latest source record: Sep 9, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

80

Actual

Start

Aug 2, 2018

Primary completion

Sep 4, 2019

Study completion Feb 2020

Sponsor

Lead sponsor
3-D Matrix Europe SASNot on our public-company list
Sponsor type
Industry
First posted
Jul 26, 2018

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.

Conditions

  • Liver Resection

Interventions

  • PuraStat®Device

    Synthetic haemostatic material

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total Time-To-HaemostasisTime frame: Intraoperatively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St James' University Hospital

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.